MRUS News and Press, Merus N.V. From 09/18/20

Youdao (DAO), Avrobio (AVRO), Merus (MRUS), and PrimeEnergy (PNRG) are four stocks recently downgraded by the POWR Ratings. If the market decline resumes, it's likely that these stocks will lead to the downside. The latest POWR Ratings  have arrived. A wide array of stocks w...

UTRECHT, The Netherlands, and CAMBRIDGE, Mass., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Merus N.V.  (Nasdaq:MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics™), today announced that Bill Lundberg...

Merus (NASDAQ: MRUS ) : Q2 GAAP EPS of -$0.54 beats by $0.12 . More news on: Merus N.V., Earnings news and commentary, Healthcare stocks news, Read more ...

– Lead program Zenocutuzumab remains on track – – Dr. Andrew Joe appointed Chief Medical Officer – – Merus extends cash runway into 2H 2022 – UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: M...

The FDA has designated Orphan Drug status for Merus's ( MRUS -0.9% ) Zenocutuzumab (Zeno) for the treatment of pancreatic cancer. More news on: Merus N.V., Healthcare stocks news, Read more ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™), today announced the appointment of Andrew J...

Caris to provide DNA and RNA molecular testing to support  patient identification and enrollment for Merus’ Zenocutuzumab Phase 1/2 eNRGy trial UTRECHT, The Netherlands and CAMBRIDGE, Mass. and IRVING, Texas, July 13, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a c...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 01, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibo...

– MCLA-128, zenocutuzumab, independent epidemiology analysis reaffirms significant clinical and commercial potential in NRG1 fusion cancers – – MCLA-117 demonstrates limited clinical activity in Phase 1 trial – – Extensive panel of novel CD3 bispecifi...